April 17, 2023 08:30 AM EDTUpdated April 19, 04:12 PM
R&D

Re­gen­eron re­veals da­ta be­hind de­pri­or­i­tized BC­MA/CD3 bis­pe­cif­ic: #AACR23

Nicole DeFeudis

Editor

OR­LAN­DO – Re­gen­eron on Mon­day re­vealed the da­ta be­hind one of its BC­MA and CD3-di­rect­ed bis­pe­cif­ic an­ti­bod­ies that it has de­cid­ed not to take for­ward …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times